---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-208139"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:59:21.369150+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# UroGen reports record Q2 JELMYTO revenue of $21.1M, positive Phase 3 data for UGN-102

## Summary
- Q2 2023 JELMYTO net revenue $21.1M (+27% YoY); net loss $24.1M ($1.03/share) vs $26.7M ($1.18) year ago.
- ENVISION Phase 3 trial met primary endpoint: 79.2% complete response at 3 months in LG-IR-NMIBC patients.
- ATLAS Phase 3 showed 55% reduction in recurrence/progression/death risk for UGN-102+TURBT vs TURBT alone.
- Completed $120M private placement of ordinary shares and pre-funded warrants to support UGN-102 launch.
- Cash and equivalents $55.3M at June 30, 2023, excluding $120M proceeds; FY revenue guidance $76-86M.

## SEC filing metadata
- accession: 0001193125-23-208139
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312523208139/0001193125-23-208139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312523208139/d509909d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-208139
- JSON: https://secwatch.observer/filing/0001193125-23-208139.json
- Plain text: https://secwatch.observer/filing/0001193125-23-208139.txt

## Key facts
- Earnings Releases
  UroGen Pharma Ltd. reported the second quarter ended June 30, 2023 results: revenue $21.1 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $21.1 million
  - Result: reported results
  source text: UroGen reported net product revenue of JELMYTO for the second quarter 2023 of $21.1 million, compared to $16.6 million in the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312523208139/0001193125-23-208139-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.